Patents by Inventor Philip Livingston

Philip Livingston has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRITERPENE SAPONIN ANALOGUES
    Publication number: 20240327443
    Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.
    Type: Application
    Filed: June 4, 2024
    Publication date: October 3, 2024
    Applicants: ADJUVANCE TECHNOLOGIES, INC., MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: David Y. GIN, Eric CHEA, Alberto FERNANDEZ-TEJADA, Jeffrey GARDNER, Jason LEWIS, Philip LIVINGSTON, J. Tyler MARTIN, Lars NORDSTROEM, Naga Vara Kishore PILLARSETTY, Govind RAGUPATHI, Derek TAN
  • Triterpene saponin analogues
    Patent number: 12037355
    Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.
    Type: Grant
    Filed: March 8, 2023
    Date of Patent: July 16, 2024
    Assignees: ADJUVANCE TECHNOLOGIES, INC., MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: David Y. Gin, Eric Chea, Alberto Fernandez-Tejada, Jeffrey Gardner, Jason Lewis, Philip Livingston, J. Tyler Martin, Lars Nordstroem, Naga Vara Kishore Pillarsetty, Govind Ragupathi, Derek Tan
  • TRITERPENE SAPONIN ANALOGUES
    Publication number: 20230219991
    Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.
    Type: Application
    Filed: March 8, 2023
    Publication date: July 13, 2023
    Applicants: ADJUVANCE TECHNOLOGIES, INC., MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: David Y. GIN, Eric CHEA, Alberto FERNANDEZ-TEJADA, Jeffrey GARDNER, Jason LEWIS, Philip LIVINGSTON, J. Tyler MARTIN, Lars NORDSTROEM, Naga Vara Kishore PILLARSETTY, Govind RAGUPATHI, Derek TAN
  • TRITERPENE SAPONINS, METHODS OF SYNTHESIS AND USES THEREOF
    Publication number: 20230131867
    Abstract: The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.
    Type: Application
    Filed: September 19, 2022
    Publication date: April 27, 2023
    Inventors: David GIN, Michelle ADAMS, Kai DENG, Philip LIVINGSTON, Govindaswami RAGUPATHI, Eric CHEA, Alberto FERNANDEZ-TEJADA, Lars Ulrik NORDSTROEM, William WALKOWICZ, Jeffrey GARDNER, Derek TAN
  • Triterpene saponins, methods of synthesis and uses thereof
    Patent number: 11447515
    Abstract: The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: September 20, 2022
    Assignee: SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: David Gin, Michelle Adams, Kai Deng, Philip Livingston, Govindaswami Ragupathi, Eric Chea, Alberto Fernandez-Tejada, Lars Ulrik Nordstroem, William Walkowicz, Jeffrey Gardner, Derek Tan
  • TRITERPENE SAPONIN ANALOGUES
    Publication number: 20210283248
    Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.
    Type: Application
    Filed: April 25, 2018
    Publication date: September 16, 2021
    Applicants: Adjuvance Technologies, Inc., Memorial Sloan Kettering Cancer Center
    Inventors: Philip LIVINGSTON, Govind RAGUPATHI, Jeffrey GARDNER, J Tyler MARTIN
  • Triterpene saponin analogues
    Patent number: 10906926
    Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: February 2, 2021
    Assignees: ADJUVANCE TECHNOLOGIES, INC., MEMORIAL SLOAN KETTERING CANCER
    Inventors: David Y. Gin, Eric Chea, Alberto Fernandez-Tejada, Jeffrey Gardner, Jason Lewis, Philip Livingston, J. Tyler Martin, Lars Nordstroem, Naga Vara Kishore Pillarsetty, Govind Ragupathi, Derek Tan
  • TRITERPENE SAPONIN ANALOGUES
    Publication number: 20210002316
    Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.
    Type: Application
    Filed: August 27, 2020
    Publication date: January 7, 2021
    Applicants: ADJUVANCE TECHNOLOGIES, INC., MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: David Y. GIN, Eric CHEA, Alberto FERNANDEZ-TEJADA, Jeffrey GARDNER, Jason LEWIS, Philip LIVINGSTON, J. Tyler MARTIN, Lars NORDSTROEM, Naga Vara Kishore PILLARSETTY, Govind RAGUPATHI, Derek TAN
  • TRITERPENE SAPONIN ANALOGUES
    Publication number: 20200239509
    Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.
    Type: Application
    Filed: March 23, 2020
    Publication date: July 30, 2020
    Applicants: ADJUVANCE TECHNOLOGIES, INC., MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: David Y. GIN (Deceased), Eric CHEA, Alberto FERNANDEZ-TEJADA, Jeffrey GARDNER, Jason LEWIS, Philip LIVINGSTON, J. Tyler MARTIN, Lars NORDSTROEM, Naga Vara Kishore PILLARSETTY, Govind RAGUPATHI, Derek TAN
  • TRITERPENE SAPONIN ANALOGUES
    Publication number: 20200164065
    Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.
    Type: Application
    Filed: April 25, 2018
    Publication date: May 28, 2020
    Applicant: ADJUVANCE TECHNOLOGIES, INC.
    Inventors: Jeffrey GARDNER, Philip LIVINGSTON, J Tyler MARTIN
  • TRITERPENE SAPONIN ANALOGUES
    Publication number: 20180327436
    Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.
    Type: Application
    Filed: November 4, 2016
    Publication date: November 15, 2018
    Applicant: ADJUVANCE TECHNOLOGIES, INC.
    Inventors: David Y. GIN (Deceased), Eric CHEA, Alberto FERNANDEZ-TEJADA, Jeffrey GARDNER, Jason LEWIS, Philip LIVINGSTON, J. Tyler MARTIN, Lars NORDSTROEM, Naga Vara Kishore PILLARSETTY, Govind RAGUPATHI, Derek TAN
  • TRITERPENE SAPONINS, METHODS OF SYNTHESIS AND USES THEREOF
    Publication number: 20170283450
    Abstract: The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.
    Type: Application
    Filed: June 16, 2017
    Publication date: October 5, 2017
    Inventors: David GIN, Michelle ADAMS, Kai DENG, Philip LIVINGSTON, Govindaswami RAGUPATHI, Eric CHEA, Alberto FERNANDEZ-TEJADA, Lars Ulrik NORDSTROEM, William WALKOWICZ, Jeffrey GARDNER, Derek TAN
  • Triterpene saponins, methods of synthesis and uses thereof
    Patent number: 9718850
    Abstract: The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: August 1, 2017
    Assignee: MEMORIAL SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: David Gin, Michelle Adams, Kai Deng, Philip Livingston, Govindaswami Ragupathi, Eric Chea, Alberto Fernandez-Tejada, Lars Ulrik Nordstroem, William Walkowicz, Jeffrey Gardner, Derek Tan
  • Glycopeptide constructs and uses thereof
    Patent number: 9598466
    Abstract: Glycopeptide conjugates, and methods of making and using such conjugates are disclosed. Certain glycopeptide conjugates comprise tumor associated carbohydrate antigens and peptide epitopes. Certain glycopeptide conjugates comprise cyclic peptide scaffolds that display carbohydrate antigens in a clustered fashion. The immunogenicity of select glycopeptide conjugates is demonstrated.
    Type: Grant
    Filed: July 13, 2009
    Date of Patent: March 21, 2017
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Samuel J. Danishefsky, Jianglong Zhu, Dongjoo Lee, Philip Livingston, Govind Ragupathi
  • TRITERPENE SAPONINS, METHODS OF SYNTHESIS AND USES THEREOF
    Publication number: 20150086585
    Abstract: The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.
    Type: Application
    Filed: September 24, 2014
    Publication date: March 26, 2015
    Inventors: David GIN, Michaelle ADAMS, Kai DENG, Nicholas PERL, Annie WON, Philip LIVINGSTON, Govind RAGUPATHI
  • Triterpene saponins, methods of synthesis, and uses thereof
    Patent number: 8889842
    Abstract: The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: November 18, 2014
    Assignee: Sloan-Kettering Insititute for Cancer Research
    Inventors: David Y. Gin, Michelle Adams, Kai Deng, Nicholas Perl, Annie Won, Philip Livingston, Govind Ragupathi
  • TRITERPENE SAPONINS, METHODS OF SYNTHESIS, AND USES THEREOF
    Publication number: 20130011421
    Abstract: The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.
    Type: Application
    Filed: September 13, 2012
    Publication date: January 10, 2013
    Applicant: Sloan-Kettering Institute for Cancer Research
    Inventors: David Gin, Michelle Adams, Kai Deng, Nicholas Perl, Annie Won, Philip Livingston, Govind Ragupathi
  • Triterpene saponins, methods of synthesis, and uses thereof
    Patent number: 8283456
    Abstract: The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.
    Type: Grant
    Filed: April 8, 2009
    Date of Patent: October 9, 2012
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: David Gin, Michelle Adams, Kai Deng, Nicholas Perl, Annie Won, Philip Livingston, Govind Ragupathi
  • TRITERPENE SAPONINS, METHODS OF SYNTHESIS, AND USES THEREOF
    Publication number: 20110300177
    Abstract: The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.
    Type: Application
    Filed: April 8, 2009
    Publication date: December 8, 2011
    Inventors: David Gin, Michelle Adams, Kai Deng, Nicholas Perl, Annie Won, Philip Livingston, Govind Ragupathi
  • GLYCOPEPTIDE CONSTRUCTS AND USES THEREOF
    Publication number: 20110229510
    Abstract: Glycopeptide conjugates, and methods of making and using such conjugates are disclosed. Certain glycopeptide conjugates comprise tumor associated carbohydrate antigens and peptide epitopes. Certain glycopeptide conjugates comprise cyclic peptide scaffolds that display carbohydrate antigens in a clustered fashion. The immunogenicity of select glycopeptide conjugates is demonstrated.
    Type: Application
    Filed: July 13, 2009
    Publication date: September 22, 2011
    Applicant: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
    Inventors: Samuel J. Danishefsky, Jianglong Zhu, Qian Wan, Insik Jeon, Woohan Kim, Pavel Nagorny, Dongjoo Lee, Philip Livingston, Govind Ragupathi